944 related articles for article (PubMed ID: 30665053)
1. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
2. [Phases 0, 1 and 2 oncology clinical trials: current questions].
Penel N; Fournier C; Stéphanie C
Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
[TBL] [Abstract][Full Text] [Related]
3. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
4. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
Feinberg J; Japour AJ
Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
[TBL] [Abstract][Full Text] [Related]
5. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
6. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
Hurria A; Dale W; Mooney M; Rowland JH; Ballman KV; Cohen HJ; Muss HB; Schilsky RL; Ferrell B; Extermann M; Schmader KE; Mohile SG;
J Clin Oncol; 2014 Aug; 32(24):2587-94. PubMed ID: 25071116
[TBL] [Abstract][Full Text] [Related]
7. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial designs for targeted agents.
Ma BB; Britten CD; Siu LL
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
[TBL] [Abstract][Full Text] [Related]
9. Ethics of Pharma Clinical Trials in the Era of Precision Oncology.
Turner JH
Cancer Biother Radiopharm; 2021 Feb; 36(1):1-9. PubMed ID: 32935997
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
11. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
12. Interim analyses in clinical trials: why do we plan them?
Fossâ SD; Skovlund E
J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
[No Abstract] [Full Text] [Related]
13. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
Gupta S; Smith TR; Broekman ML
J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
[TBL] [Abstract][Full Text] [Related]
14. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
Drugs R D; 2004; 5(5):293-6. PubMed ID: 15357628
[TBL] [Abstract][Full Text] [Related]
15. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
16. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
17. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
18. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
19. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
